ZVRA Stock Forecast & Price Target

Zevra Therapeutics is attractive because its U.S. MIPLYFFA launch is proving durable, with 2Q26 net sales of $30.2MM, 184 cumulative enrollment forms, and a more consistent patient-finding funnel supported by claims, EMR, genetic testing, and disease-awareness efforts. The stock’s fundamental case is strengthened by a large underpenetrated NPC market—management estimates 300–350 diagnosed U.S. patients versus roughly 900 total prevalent patients—plus high retention, a 69% covered-life access rate, and 50% of treated patients being adults, which expands the runway beyond the initial known population. Zevra also has more than $260M of cash and investments, no debt, and additional upside from the ongoing Europe re-examination and celiprolol, which could leverage the same rare-disease infrastructure into a second franchise.

Zevra Therapeutics is facing a weak fundamental setup because its Miplyffa launch carries meaningful commercial execution, reimbursement, and competitive risk, including the possibility that a recent competitor approval could reduce demand, limit payer access, and slow the sales ramp. The company also faces substantial regulatory and clinical uncertainty, since failure to obtain EMA approval or setbacks in current and future pipeline programs could reduce optionality and impair both approval prospects and future growth. Financially, management commentary and updated assumptions led to lower near-term ROW/EAP revenue estimates, while a 10.3% WACC, a 15.5x exit multiple on 2031 estimates, and a history of losses underscore liquidity pressure and the likelihood of needing additional capital.